Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas / 中华医学杂志(英文版)

ABSTRACT

<p><b>OBJECTIVE</b>To highlight recent researches which may show promise for histomolecular classification and new treatments for gliomas.</p><p><b>DATA SOURCES</b>All articles cited in this review were mainly searched from PubMed, which were published in English from 1996 to 2010.</p><p><b>STUDY SELECTION</b>Original articles and critical reviews selected were relevant to the isocitrate dehydrogenase-1/2 mutation in gliomas and other tumors.</p><p><b>RESULTS</b>Extraordinary high rates of somatic mutations in isocitrate dehydrogenase-1/2 occur in the majority of World Health Organization grade II and grade III gliomas as well as grade IV secondary glioblastomas. Isocitrate dehydrogenase-1/2 mutations are associated with younger age at diagnosis and a better prognosis in patients with mutated tumors. The functional role of isocitrate dehydrogenase-1/2 mutations in the pathogenesis of gliomas is still unclear.</p><p><b>CONCLUSION</b>Isocitrate dehydrogenase-1/2 mutations define a specific subtype of gliomas and may have great significance in the diagnosis, prognosis, and treatment of patients with these tumors.</p>